
Neville D Yeomans

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2332582/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Demographics and distribution of australia's medical immigrant workforce. Journal of Migration and Health, 2022, 5, 100109.	1.6	5
2	International medical graduates (<scp>IMGs</scp>) in culâ€deâ€sacs: "lost in the labyrinth―revisited?. Medical Journal of Australia, 2022, 216, 553-555.	0.8	2
3	Editorial: risk of gastric and duodenal ulcers among new users of lowâ€dose aspirin. Alimentary Pharmacology and Therapeutics, 2022, 56, 334-335.	1.9	0
4	Demographics and performance of candidates in the examinations of the Australian Medical Council, 1978–2019. Medical Journal of Australia, 2021, 214, 54.	0.8	5
5	Sirolimus in Liver Transplant Recipients With Hepatocellular Carcinoma. Journal of Investigative Surgery, 2020, 33, 389-390.	0.6	0
6	Letter: mechanistic target of rapamycin inhibitors—do they impact on recurrence of hepatocellular carcinoma after liver transplantation? Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 117-120.	1.9	0
7	Systematic review with metaâ€analysis: sirolimus―or everolimusâ€based immunosuppression following liver transplantation for hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2019, 49, 1260-1273.	1.9	60
8	Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflammatory Bowel Diseases, 2019, 25, 1169-1186.	0.9	63
9	Helicobacter pylori and lowâ€dose aspirin ulcer risk: A metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 517-525.	1.4	15
10	Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the <scp>PRECISION</scp> trial. Alimentary Pharmacology and Therapeutics, 2018, 47, 1453-1463.	1.9	41
11	The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial. Rheumatology, 2018, 57, 1364-1369.	0.9	3
12	Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen,ÂorÂlbuprofen. Journal of the American College of Cardiology, 2018, 71, 1741-1751.	1.2	35
13	Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 537-546.	2.9	33
14	Acute Pancreatitis With Long-Term Celecoxib VS. Ibuprofen or Naproxen: Data From the PRECISION Trial. American Journal of Gastroenterology, 2018, 113, 1053-1054.	0.2	2
15	Letter: the effect of sirolimus on recurrence and survival in liver transplant recipients with hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2018, 48, 1330-1331.	1.9	3
16	Editorial: gastrointestinal safety of <scp>COX</scp> â€⊋ selective and nonselective <scp>NSAID</scp> s—the impact of the <scp>PRECISION</scp> trial. Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1546-1547.	1.9	0
17	The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial. American Journal of Medicine, 2017, 130, 1415-1422.e4.	0.6	87
	Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis:		

the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50

38, 3282-3292.

18

#	Article	IF	CITATIONS
19	Health care in late Qing Dynasty and Republican China: Western influences, Chinese solutions. Medical Journal of Australia, 2016, 205, 503-505.	0.8	0
20	Systematic review with metaâ€analysis: fundic gland polyps and proton pump inhibitors. Alimentary Pharmacology and Therapeutics, 2016, 44, 915-925.	1.9	55
21	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New England Journal of Medicine, 2016, 375, 2519-2529.	13.9	607
22	Incretinâ€based therapies for the treatment of nonâ€alcoholic fatty liver disease: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 23-31.	1.4	70
23	Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis. Journal of Crohn's and Colitis, 2016, 10, 979-988.	0.6	56
24	Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?. BMC Medicine, 2015, 13, 56.	2.3	8
25	Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies. Journal of Thrombosis and Thrombolysis, 2014, 38, 11-23.	1.0	17
26	Students coached for an admission test perform less well throughout a medical course. Internal Medicine Journal, 2013, 43, 927-932.	0.5	7
27	The JGH foundation: Facilitating education and research in the Asia-Pacific. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1545-1545.	1.4	2
28	Lack of effect of omeprazole, a potent inhibitor of gastric (H++ K+) ATPase, on hepatic lysosomal integrity and enzyme activity. Journal of Pharmacy and Pharmacology, 2011, 38, 158-160.	1.2	9
29	The ulcer sleuths: The search for the cause of peptic ulcers. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 35-41.	1.4	44
30	Aspirin: Old drug, new uses and challenges*. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 426-431.	1.4	42
31	Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. Expert Review of Gastroenterology and Hepatology, 2011, 5, 447-455.	1.4	4
32	Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut, 2011, 60, 1170-1177.	6.1	158
33	Predictors of gastroduodenal erosions in patients taking lowâ€dose aspirin. Alimentary Pharmacology and Therapeutics, 2010, 31, 143-149.	1.9	36
34	Fifty years of Australian gastroenterology and hepatology: A golden era of contributions to the region. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1579-1580.	1.4	0
35	Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. American Heart Journal, 2009, 157, 606-612.	1.2	115
36	Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with non-steroidal anti-inflammatory drugs. Current Medical Research and Opinion, 2009, 25, 2785-2793.	0.9	30

#	Article	IF	CITATIONS
37	Overview of 50 years' progress in upper gastrointestinal diseases. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, S2-4.	1.4	6
38	Systematic review: ulcer definition in NSAID ulcer prevention trials. Alimentary Pharmacology and Therapeutics, 2008, 27, 465-472.	1.9	55
39	Prospective study of cardiac troponin I release in patients with upper gastrointestinal bleeding. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 938-942.	1.4	24
40	Efficacy of Esomeprazole (20 mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin. American Journal of Gastroenterology, 2008, 103, 2465-2473.	0.2	193
41	Does practice make perfect? The effect of coaching and retesting on selection tests used for admission to an Australian medical school. Medical Journal of Australia, 2008, 189, 270-273.	0.8	58
42	Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of nonâ€steroidal antiâ€inflammatory drugs. Alimentary Pharmacology and Therapeutics, 2007, 25, 813-821.	1.9	20
43	Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Research and Therapy, 2007, 9, R17.	1.6	19
44	Augmented gp130â€mediated cytokine signalling accompanies human gastric cancer progression. Journal of Pathology, 2007, 213, 140-151.	2.1	94
45	Emerging leaders of gastroenterology and hepatology in the Asia-Pacific region. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 961-962.	1.4	4
46	Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors. American Journal of Gastroenterology, 2006, 101, 701-710.	0.2	255
47	Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?. International Journal of Clinical Practice, 2006, 60, 1401-1407.	0.8	19
48	Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Alimentary Pharmacology and Therapeutics, 2005, 22, 795-801.	1.9	232
49	Improvements with Esomeprazole in Patients with Upper Gastrointestinal Symptoms Taking Non-Steroidal Antiinflammatory Drugs, Including Selective COX-2 Inhibitors. American Journal of Gastroenterology, 2005, 100, 1028-1036.	0.2	86
50	Impact of cyclooxygenase-2 inhibitors: are they fulfilling their promises?. Internal Medicine Journal, 2004, 34, 145-147.	0.5	3
51	Intravenous Lansoprazole. Drugs, 2004, 64, 2090.	4.9	0
52	Future directions of medical education in Australia. Internal Medicine Journal, 2003, 33, 360-361.	0.5	0
53	Insights into the Mechanisms of Gastric Adaptation to Aspirin-Induced Injury: A Role for Regenerating Protein but Not Trefoil Peptides. Laboratory Investigation, 2003, 83, 1415-1425.	1.7	14
54	COX-2 Inhibition Versus Gastroprotection with Dual COX Inhibitors: An Evidence-Based Approach. Current Pharmaceutical Design, 2003, 9, 2221-2228.	0.9	10

#	Article	IF	CITATIONS
55	Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut, 2002, 51, 344-350.	6.1	44
56	Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut, 2002, 51, 336-343.	6.1	34
57	Nonsteroidal antiinflammatory drugs and the stomach. Current Opinion in Gastroenterology, 2002, 18, 658-662.	1.0	1
58	Biliary epithelial trefoil peptide expression is increased in biliary diseases. Histopathology, 2002, 40, 261-268.	1.6	46
59	Management of peptic ulcer disease not related to Helicobacter. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 488-494.	1.4	13
60	Approaches to healing and prophylaxis of nonsteroidal anti-inflammatory drug–associated ulcers. American Journal of Medicine, 2001, 110, S24-S28.	0.6	7
61	Adaptation of the stomach to injury from nonsteroidal anti-inflammatory drugs. Current Gastroenterology Reports, 2001, 3, 1-2.	1.1	1
62	Spatio-temporal expression of trefoil peptide following severe gastric ulceration in the rat implicates it in late-stage repair processes. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 506-512.	1.4	19
63	Augmented Intestinal Trefoil Factor (TFF3) and Loss of pS2 (TFF1) Expression Precedes Metaplastic Differentiation of Gastric Epithelium. Laboratory Investigation, 2001, 81, 397-408.	1.7	92
64	Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion?. Alimentary Pharmacology and Therapeutics, 2000, 14, 267-271.	1.9	30
65	Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. Alimentary Pharmacology and Therapeutics, 2000, 14, 751-758.	1.9	37
66	Resistance to apoptosis is a mechanism of adaptation of rat stomach to aspirin. American Journal of Physiology - Renal Physiology, 2000, 278, G839-G846.	1.6	27
67	Safer use of NSAIDs in Australia. Medical Journal of Australia, 2000, 172, 518-518.	0.8	Ο
68	The Nonsteroidal Anti-Inflammatory Drugs Controversy. Gastroenterology Clinics of North America, 2000, 29, 791-805.	1.0	13
69	Use of mRNA differential display to identify 3 genes involved in adaptation to injury in the stomach. Gastroenterology, 2000, 118, A660.	0.6	1
70	ls it time to adopt proton pump inhibitors in the prevention of non-steroidal anti-inflammatory drug gastropathy?. Digestive and Liver Disease, 2000, 32, 209-210.	0.4	2
71	Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut, 1999, 44, 636-642.	6.1	126
72	Prevention of the Gastrointestinal Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs. Drug Safety, 1999, 21, 503-512.	1.4	18

#	Article	IF	CITATIONS
73	A clinical approach to management of patients with non-steroidal anti-inflammatory gastropathy. Italian Journal of Gastroenterology and Hepatology, 1999, 31 Suppl 1, S89-92.	0.5	0
74	Oral human spasmolytic polypeptide protects against aspirininduced gastric injury in rats. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 363-370.	1.4	40
75	Selective COX-2 inhibitors: Are they safe for the stomach?. Gastroenterology, 1998, 115, 227-229.	0.6	13
76	Evolving Strategies for Managing Nonsteroidal Anti-inflammatory Drug-Associated Ulcers: Chairmen's Introduction. American Journal of Medicine, 1998, 104, 1S.	0.6	1
77	New Data on Healing of Nonsteroidal Anti-inflammatory Drug–Associated Ulcers and Erosions 11More complete descriptions of the two studies outlined in this article have been published elsewhere.[1, 2]. American Journal of Medicine, 1998, 104, 56S-61S.	0.6	28
78	Chairmen's Conclusion. American Journal of Medicine, 1998, 104, 96S.	0.6	1
79	A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs. New England Journal of Medicine, 1998, 338, 719-726.	13.9	723
80	Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs. New England Journal of Medicine, 1998, 338, 727-734.	13.9	840
81	Trefoil peptides are early markers of gastrointestinal maturation in the rat. International Journal of Developmental Biology, 1998, 42, 783-9.	0.3	17
82	Temporal expression of trefoil peptides in the TGF-alpha knockout mouse after gastric ulceration. American Journal of Physiology - Renal Physiology, 1997, 272, G1540-G1549.	1.6	21
83	Repair of rat gastric mucosa: effect of 16,16-dimethyl prostaglandin E2. Digestive Diseases and Sciences, 1997, 42, 654-660.	1.1	7
84	Helicobacter heilmannii (formerly Gastrospirillum): Association with pig and human gastric pathology. Gastroenterology, 1996, 111, 244-246.	0.6	30
85	Gastric mucosal adaptation to diclofenac injury. Digestive Diseases and Sciences, 1996, 41, 32-39.	1.1	19
86	Adaptation of the gastric epithelium to injury is maintained in vitro and is associated with increased TGF-α expression. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 259-263.	1.4	4
87	Correlation between transmucosal potential difference and morphological damage during aspirin injury of gastric mucosa in rats. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 264-269.	1.4	8
88	Adult asthma and gastroâ€oesophageal reflux: the effects of omeprazole therapy on asthma. Australian and New Zealand Journal of Medicine, 1996, 26, 671-676.	0.5	75
89	INDOMETHACIN DAMAGE TO RAT GASTRIC MUCOSA IS MARKEDLY DEPENDENT ON LUMINAL pH. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 432-434.	0.9	86
90	Effects of acid suppression on microbial flora of upper gut. Digestive Diseases and Sciences, 1995, 40, 81S-95S.	1.1	45

#	Article	IF	CITATIONS
91	Maintenance therapy for duodenal ulcer with proton pump blockers. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 110-111.	1.4	3
92	Gastric microbleeding following single and repeated dosing with naproxen. Alimentary Pharmacology and Therapeutics, 1995, 9, 655-659.	1.9	2
93	Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety Gut, 1994, 35, 590-598.	6.1	170
94	Efficacy of 12 Months' Misoprostol as Prophylaxis against IMSAID-induced Gastric Ulcers:A placebo-controlled trial. Scandinavian Journal of Rheumatology, 1994, 23, 171-176.	0.6	73
95	Hepatic Kupffer cell function: the efficiency of uptake and intracellular degradation of 14C-labelled mitochondria is reduced in aged rats. Mechanisms of Ageing and Development, 1994, 73, 157-168.	2.2	10
96	Gastric mucosal defensive factors: The therapeutic strategy. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, S104-S108.	1.4	4
97	Role of bacterial overgrowth in gastric carcinogenesis. , 1994, , 475-482.		2
98	Omeprazole: short- and long-term safety. Toxicological Reviews, 1994, 13, 145-56.	0.5	6
99	Gastric mucosal damage induced by nonsalicylate nonsteroidal antiinflammatory drugs in rats is mediated systemically. Digestive Diseases and Sciences, 1993, 38, 2038-2042.	1.1	14
100	High prevalence of duodenal ulcer in Indochinese immigrants attending an Australian university hospital. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 128-132.	1.4	5
101	The Role of Acid Regulation in the Treatment of NSAID-induced Mucosal Damage. Digestion, 1992, 51, 3-10.	1.2	15
102	Adaptation of rat gastric mucosa to repeated doses of non-salicylate non-steroidal anti-inflammatory drugs. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 586-590.	1.4	19
103	Nonsteroidal antiâ€inflammatory drug gastropathy – is it preventable?. Australian and New Zealand Journal of Medicine, 1992, 22, 685-691.	0.5	4
104	AGEING HAS NO EFFECT ON THE VOLUME DENSITY OF HEPATOCYTES, RETICULOENDOTHELIAL CELLS OR THE EXTRACELLULAR SPACE IN LIVERS OF FEMALE SPRAGUE-DAWLEY RATS. Clinical and Experimental Pharmacology and Physiology, 1992, 19, 537-539.	0.9	13
105	Nonsteroidal anti-inflammatory drug gastropathy – is it preventable?. Internal Medicine Journal, 1992, 22, 685-691.	0.5	0
106	<i>Helicobacter pylori</i> and duodenal ulcer. Journal of Gastroenterology and Hepatology (Australia), 1991, 6, 177-178.	1.4	7
107	Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer British Journal of Clinical Pharmacology, 1991, 31, 166-170.	1.1	22
108	Repair and Healing of Established Gastric Mucosal Injury. Journal of Clinical Gastroenterology, 1991, 13, S37-S41.	1.1	15

#	Article	IF	CITATIONS
109	Sucralfate protection against ethanol-induced injury of rat gastric mucosa in vitro and in vivo. Journal of Gastroenterology and Hepatology (Australia), 1988, 3, 227-233.	1.4	2
110	Ethanol damage to rat gastric mucosa is unlikely to be mediated by ethanol. Experimental Pathology, 1988, 33, 173-177.	0.5	0
111	Bacteria in ulcer pathogenesis. Bailliere's Clinical Gastroenterology, 1988, 2, 573-591.	0.9	11
112	Effect of 'weekend therapy' with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients Gut, 1988, 29, 1715-1720.	6.1	14
113	CAMPYLOBACTER PYLORI – GASTRODUODENAL PATHOGEN OR OPPORTUNISTIC BYSTANDER?. Australian and New Zealand Journal of Medicine, 1988, 18, 555-556.	0.5	7
114	THE DIAGNOSTIC PROCESS. A MODEL FOR CLINICAL TEACHERS. By John I. Balla. Australian and New Zealand Journal of Medicine, 1987, 17, 97-97.	0.5	0
115	Relapse of duodenal ulceration after healing with omeprazole. Medical Journal of Australia, 1987, 147, 595-597.	0.8	11
116	Relapse of duodenal ulceration after healing with omeprazole. Medical Journal of Australia, 1987, 147, 595-7.	0.8	1
117	The effectiveness of ranitidine in reducing gastric acidâ€secretion decreases with continued therapy British Journal of Clinical Pharmacology, 1986, 22, 663-668.	1.1	43
118	The effect of omeprazole on 24 h intragastric pH and fasting plasma gastrin during low dosage (10 mg) in the morning or the evening. Journal of Gastroenterology and Hepatology (Australia), 1986, 1, 289-295.	1.4	3
119	Should we delete the digraphs ("ae―and "oeâ€) from Australian medical writing?. Medical Journal of Australia, 1986, 144, 667-668.	0.8	1
120	A 75 YEAR OLD MAN WITH SIDEROBLASTIC ANEMIA. Australian and New Zealand Journal of Medicine, 1986, 16, 249-255.	0.5	1
121	Pericanalicular location of hepatocyte lysosomes and effects of fasting: A morphometric analysis. Hepatology, 1986, 6, 305-311.	3.6	17
122	ETHANOL IMPAIRS BILIARY LYSOSOMAL ENZYME RELEASE IN RATS. Clinical and Experimental Pharmacology and Physiology, 1986, 13, 745-750.	0.9	6
123	Ethanol-induced cell damage in cultured rat antral mucosa assessed by chromium-51 release. Digestive Diseases and Sciences, 1986, 31, 853-858.	1.1	10
124	Absence of histopathological response to cadmium in gill and digestive diverticula of the mussel,Mytilus edulis. Bulletin of Environmental Contamination and Toxicology, 1986, 36, 146-149.	1.3	0
125	Double-Blind Comparison of Omeprazole, 10 mg Versus 30 mg, for Healing Duodenal Ulcers. Scandinavian Journal of Gastroenterology, 1986, 21, 171-172.	0.6	2
126	Morning or Evening Dosing with Low-Dose Omeprazole: Effects on 24-Hour Gastric Acidity Profiles in Duodenal Ulcer Patients. Scandinavian Journal of Gastroenterology, 1986, 21, 152-153.	0.6	4

#	Article	IF	CITATIONS
127	CLINICS IN GASTROENTEROLOGY. NON-INVASIVE RADIOLOGY. Australian and New Zealand Journal of Medicine, 1985, 15, 49-49.	0.5	0
128	A 70 YEAR OLD MAN WITH PORTAL HYPERTENSION. Australian and New Zealand Journal of Medicine, 1985, 15, 461-468.	0.5	1
129	RELAPSE OF DUODENAL ULCERS AFTER CIMETIDINE TREATMENT: IDOL â€~INDECENTLY' ASSAULTED?. Austra and New Zealand Journal of Medicine, 1985, 15, 291-292.	ilian 0.5	2
130	Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers BMJ: British Medical Journal, 1985, 290, 601-603.	2.4	41
131	Cimetidine versus ranitidine in short term healing of duodenal ulcers Gut, 1985, 26, 642-642.	6.1	5
132	Omeprazole: A Study of Its Inhibition of Gastric pH and Oral Pharmacokinetics After Morning or Evening Dosage. Gastroenterology, 1985, 88, 64-69.	0.6	186
133	Gastric mucus — chemistry, synthesis and secretion. Medical Journal of Australia, 1985, 142, S7-8.	0.8	2
134	The gastric mucus cells — structural considerations. Medical Journal of Australia, 1985, 142, S3-4.	0.8	0
135	Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine. Biomedical Applications, 1983, 278, 311-319.	1.7	37
136	Effect of daily oral omeprazole on 24 hour intragastric acidity BMJ: British Medical Journal, 1983, 287, 1378-1379.	2.4	10
137	DOUBLE-BLIND CONTROLLED TRIAL OF RANITIDINE VERSUS CIMETIDINE IN THE TREATMENT OF DUODENAL ULCERATION. Australian and New Zealand Journal of Medicine, 1982, 12, 547-549.	0.5	8
138	Comparative distribution of pepsinogen in the chordate gastric mucosa from representatives of five classes. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1982, 72, 145-147.	0.2	0
139	Changes in volume of stored mucus in pit and surface cells during their maturation and migration in the antral mucosa of the mouse. Cell and Tissue Research, 1982, 227, 459-463.	1.5	2
140	BIOAVAILABILITY OF VALPROATE AFTER GASTRIC AND DIRECT INTESTINAL ADMINISTRATION IN RATS. Clinical and Experimental Pharmacology and Physiology, 1982, 9, 173-177.	0.9	14
141	Effect of Cigarette Smoking on Duodenogastric Reflux of Bile Acids*. Australian and New Zealand Journal of Medicine, 1981, 11, 347-350.	0.5	5
142	Fine structure of the gastric mucous and endocrine cells of the toad, Bufo marinus. Cell and Tissue Research, 1981, 218, 663-8.	1.5	14
143	Synthesis and secretion of glycoproteins by mucosa of rat gastric antrum in organ culture. Digestive Diseases and Sciences, 1980, 25, 295-301.	1.1	18
144	Nonglycoprotein "Cores―in Gastric Mucous Granules. Gastroenterology, 1980, 78, 1658.	0.6	2

#	Article	IF	CITATIONS
145	Nonglycoprotein "cores" in gastric mucous granules. Gastroenterology, 1980, 78, 1658-9.	0.6	1
146	Ultrastructure and cytochemistry of the gastric mucosa of a reptile, Tiliqua scincoides. Cell and Tissue Research, 1979, 197, 281-94.	1.5	29
147	Secretory granules in differentiating mucous cells in fetal rat fundic mucosa. Gastroenterologie Clinique Et Biologique, 1978, 2, 925-8.	0.9	3
148	Epithelial cell proliferation and migration in the developing rat gastric mucosa. Developmental Biology, 1976, 53, 206-216.	0.9	39
149	Maturation and Differentiation of Cultured Fetal Stomach. Gastroenterology, 1976, 71, 770-777.	0.6	21
150	Electron microscopic study of the repair of aspirin-induced gastric erosions. The American Journal of Digestive Diseases, 1976, 21, 533-541.	0.9	38
151	Gastrotoxic effect of parenteral aspirin. The American Journal of Digestive Diseases, 1976, 21, 833-833.	0.9	1
152	Identification of cell types in semithin epoxy sections of gastric fundic mucosa Journal of Histochemistry and Cytochemistry, 1976, 24, 755-756.	1.3	11
153	Maturation and differentiation of cultured fetal stomach. Effects of corticosteroids, pentagastrin, and cytochalasin B. Gastroenterology, 1976, 71, 770-7.	0.6	3
154	ASPIRIN AND CHRONIC GASTRIC ULCER. Medical Journal of Australia, 1976, 1, 370.	0.8	1
155	An ultrastructural sonnet. Journal of Microscopy, 1975, 103, 131-131.	0.8	2
156	Small intestinal malabsorption of vitamin B12 in iron-deficient rats. Pathology, 1975, 7, 35-44.	0.3	3
157	Effect of carbenoxolone sodium on aspirin-induced injury of the rat gastric mucosa. The American Journal of Digestive Diseases, 1974, 19, 217-222.	0.9	8
158	The Mallory-Weiss Syndrome. BMJ: British Medical Journal, 1974, 1, 140-143.	2.4	26
159	Ultrastructural and cytochemical study of mucous granules in surface and crypt cells of rat gastric mucosa. Biologie Et Gastro-entérologie, 1974, 7, 285-90.	0.4	9
160	Adaptation of the gastric mucosa to repeated administration of aspirin in the rat. The American Journal of Digestive Diseases, 1973, 18, 881-886.	0.9	85
161	Early endoscopy in haematemesis and melaena BMJ: British Medical Journal, 1973, 2, 772-773.	2.4	2
162	Chronic gastric ulcer induced by aspirin: an experimental model. Gastroenterology, 1973, 65, 634-41.	0.6	7

#	ARTICLE	IF	CITATIONS
163	Regeneration of gastric mucosa after aspirin-induced injury in the rat. The American Journal of Digestive Diseases, 1973, 18, 773-780.	0.9	55